MindMaze Therapeutics (SIX: MMTX) has announced new real-world evidence from a multi-site program with Vibra Healthcare, demonstrating that home-based rehabilitation using MindMotion significantly increases therapy dose and improves functional outcomes. The findings, presented at the American Congress of Rehabilitation Medicine, are particularly important as the company prepares to launch MindMotion Lite, a tablet-based solution, by the end of 2026. The results address a critical gap in neurorehabilitation: maintaining high-dose, high-intensity therapy after patients leave the clinic.
The retrospective quality improvement program evaluated 177 rehabilitation episodes involving 172 adults with neurological conditions, primarily stroke, across four Vibra Healthcare outpatient sites. Participants followed an eight-week home-training program using MindMotion GO, with an optional four-week extension and periodic therapist supervision. The program found that patients completed an average of 174 minutes of active training per week, with 84.4% delivered asynchronously—without direct therapist supervision. The additional home training increased total motor-training dose by a median factor of 3.0 compared with usual outpatient therapy alone. This is a substantial increase, as higher therapy doses are strongly associated with better recovery outcomes.
Feasibility and engagement were high: 92.7% of participants successfully completed home setup, and 80.2% achieved the predefined minimum training exposure. Among surveyed participants, 83.8% of satisfaction ratings were positive. Statistically significant improvements were observed in independence (Barthel Index: +10.4 points), balance (Berg Balance Scale: +10.5 points), cognition (SLUMS: +3.4 points), and mobility (Timed Up and Go: −8.8 seconds). These gains are clinically meaningful and suggest that home-based therapy can drive comprehensive functional recovery.
“Earlier this year, we showed that MindMaze's high-dose, high-intensity therapy, integrated into inpatient rehabilitation, delivers superior functional outcomes in a resource-efficient way,” said Zach Henderson, CEO of MindMaze Therapeutics. “Now, we are demonstrating that this value can extend into the home to address a well-recognized gap in care once patients leave the clinic, in line with the 2026 AHA/ASA Guideline for Adult Stroke Rehabilitation and Recovery. These results, combined with our upcoming MindMotion Lite tablet-based solution, will help make high-quality neurotherapeutics more accessible. Together, these milestones bring us closer to our mission of making neurotherapeutics available at scale.”
The upcoming launch of MindMotion Lite is designed to deliver the full range of MindMotion GO neurotherapeutic activities with substantially reduced hardware requirements, simplifying home deployment and supporting broader adoption by healthcare providers. This is expected to be a key driver in expanding access to effective neurorehabilitation. The full poster, “High-Dose, Home-Based Neurorehabilitation Using Gamified Technology: A Multi-Site Quality Improvement Program,” is available at mindmazetherapeutics.com/mindmaze-platform/clinical-evidence.
MindMaze Therapeutics (SIX: MMTX) is a global leader in scalable precision neurotherapeutics, integrating advanced software, proprietary sensors, and AI-driven data analytics to provide a seamless continuum of care from hospital to home. The company's FDA-listed and CE-marked products address the systemic shortage of specialized clinicians, offering scalable, reimbursable solutions for stroke, Parkinson's disease, and other neurological disorders. For more information, visit www.mindmazetherapeutics.com.
These results are important because they demonstrate that home-based neurorehabilitation can achieve high training doses and significant functional improvements without direct therapist supervision, potentially reducing the burden on healthcare systems and improving patient access. As the population of stroke survivors grows, scalable solutions like MindMotion Lite could transform post-acute care. The original release is available on www.newmediawire.com.
